Recent Advances in Immunotherapy for Acute Myeloid Leukemia --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 633-636, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-771907
ABSTRACT
Currently, the traditional chemotherapeutic drugs for acute myeloid leukemia (AML) showed significant curative efficacy, including the improving long-term prognosis and the life quality of the patients, however the traditional chemotherapeuatic drugs showed the some limitatious in the aspects of enhancing the complete remission rate of newly diagnosed AML patients, overcoming the relapse after remission,as well as the primary and secondary drug-resstance to chemotherapeutics. In order to improve the long-term prognisis of patients, the immuno therapy will the best choice for these patients. This review sammarizes the main current advance of immunotherapy of AML at home and abroad, such as antibody-drug conjugate(ADC), bispecific T cell engager (BiTE), chimeric type of antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors; dendritic cell vaccination and peptide vaccines; natural killer cell (NK) therapy and so on.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Terapéutica
/
Linfocitos T
/
Leucemia Mieloide Aguda
/
Inmunoterapia Adoptiva
/
Vacunas contra el Cáncer
/
Inmunoterapia
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS